Correction
for Thakkar et al., Clin Chem 43 (1) 109-113.
Clinical Chemistry 43: 1471, 1997;
(Clinical Chemistry. 1997;43:1471.)
© 1997 American Association for Clinical Chemistry, Inc.
Corrections
In the article by H. Thakkar, D.J. Newman, P. Holownia, C.L.
Davey, C.-C. Wang, J. Lloyd, et al., entitled "Development and
validation of a particle-enhanced turbidimetric inhibition assay for
urine albumin on the Dade aca® analyzer,"
1997;43:109–13, the CV values in Table 1 are correct as printed but
the within-run and between-run SDs for the lowest-concentration samples
reported should be 0.65 and 0.89 mg/L, respectively.
In the Technical Brief by Amy B. Blase, Roger L. Sokoloff, and Katie M.
Smith, entitled "Five PSA methods compared by assaying samples with
defined PSA ratios," 1997;43:843–5, the data in Table 1 are correct,
but the column headings of the rightmost two columns should be
interchanged. That is, the data in the rightmost column refer to ACS
PSA1 results, whereas the preceding column presents ACS
PSA2 data.
In the Annual Meeting Supplement to the June 1997 issue,
Abstract 606 by S.M. Houser and P.J. Maimonis, entitled "An
analytical and clinical comparison of ACST BR with two other breast
tumor marker assays," 1997;43:S236, was erroneously omitted, having
been replaced with a duplicate of Abstract 605. The correct Abstract
606 is presented here:
CA 27.29 is a mucin glycoprotein associated with breast
cancer. It is measured by the ACST BR assay from Chiron Diagnostics
(Walpole, MA) as well as by the FDA approved Truquantr BRT assay from
Biomira Diagnostics (Toronto, Canada). The molecule is also known as CA
15-3, as measured by Centocor CA 15-3T RIA (Malvern, PA). Both Truquant
BR and ACS BR assays use a competitive format using the single
monoclonal antibody B27.29 as tracer while CA 15-3 RIA is a dual
monoclonal sandwich assay. Truquant BR and CA 15-3 RIA are manual
assays both requiring sample pre-dilution while ACS BR requires no
sample pre-dilution and runs on the fully automated, random access
ACS:180r system (Chiron Diagnostics). Within run and total %CV's for
the ACS BR assay were all 6% across the working range of the assay
with higher CV's for the manual assays. Method comparison studies
using patients with confirmed breast cancer yielded the following
results: ACS = 1.02 Truquant + 7.8, r = 0.96 and ACS = 1.06 CA 15-3 +
3.7, r = 0.96. Using a panel of 220 staged breast cancer patients, ACS
BR detected as elevated 10–20% more patients across each stage of
breast cancer than did CA 15-3 RIA. For stage IV patients, the clinical
sensitivities were 75% and 51% for ACS BR and CA 15-3 RIA
respectively. A study of longitudinal samples from patients with fully
documented clinical histories showed 100% correlation of changing CA
27.29 levels (ACS BR and Truquant BR) with disease status. In
conclusion, the ACS BR assay has superior precision to manual methods
with values equivalent to those of both Truquant BR and CA 15-3 RIA.
Moreover, the ACS BR assay accurately monitors disease status and is
informative in a higher percentage of patients than CA 15-3 RIA.
